SCHEMBL8380372

SCHEMBL8380372

COc1ccc(C(CC(=O)O)c2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
FFAR1 O14842 8/20 0.53
L3MBTL1 Q9Y468 1/20 0.48
ATM Q13315 1/20 0.47
HTRA1 Q92743 1/20 0.46
HPGD P15428 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484578 0.86 FFAR1 (0.66) KMT2AFFAR1L3MBTL1ATMHPGD
SCHEMBL18039146 0.85 FFAR1 (0.55) KMT2AFFAR1ATMFNTAFNTB
SCHEMBL18055503 0.84 FNTA (0.59) KMT2AFFAR1ATMHPGDLMNA
SCHEMBL18228824 0.84 KMT2A (0.58) KMT2AFFAR1L3MBTL1ATMHPGD
SCHEMBL7925442 0.83 SLC6A2 (0.47) FFAR1FNTAFNTB
SCHEMBL9444866 0.83 SLC6A2 (0.47) FFAR1FNTAFNTB
SCHEMBL28489153 0.81 FFAR1 (0.61) KMT2AFFAR1L3MBTL1ATMHPGD
SCHEMBL21959755 0.80 HTRA1 (0.59) KMT2AHTRA1HPGDLMNAGAA
SCHEMBL13214514 0.80 FFAR1 (0.43) KMT2AFFAR1LMNA
SCHEMBL28490573 0.78 FFAR1 (0.79) KMT2AFFAR1ATMHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107531653-B Novel difluoroketoamide derivatives 豪夫迈·罗氏有限公司 2021-10-19 CN disclosed
EP-3294718-B1 NEW DIFLUOROKETAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-04-29 EP disclosed
EP-3294718-B1 NEW DIFLUOROKETAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-04-29 EP disclosed
EP-3262026-B1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-03-18 EP disclosed
EP-3262026-B1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-03-18 EP disclosed
US-10428108-B2 Difluoroketamide derivatives HOFFMANN-LA ROCHE INC. (US) 2019-10-01 US disclosed
US-10428108-B2 Difluoroketamide derivatives HOFFMANN-LA ROCHE INC. (US) 2019-10-01 US disclosed
US-9980929-B2 Trifluoromethylpropanamide derivatives HOFFMAN-LA ROCHE INC. (US) 2018-05-29 US disclosed
US-9980929-B2 Trifluoromethylpropanamide derivatives HOFFMAN-LA ROCHE INC. (US) 2018-05-29 US disclosed
US-9980929-B2 Trifluoromethylpropanamide derivatives HOFFMAN-LA ROCHE INC. (US) 2018-05-29 US disclosed
US-20180057526-A1 NEW DIFLUOROKETAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-03-01 US disclosed
US-20180057526-A1 NEW DIFLUOROKETAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-03-01 US disclosed
CN-107531653-A Novel difluoroketoamide derivatives 豪夫迈·罗氏有限公司 2018-01-02 CN disclosed
US-20170348257-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-12-07 US disclosed
US-20170348257-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-12-07 US disclosed
US-20170348257-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-12-07 US disclosed
WO-2016180751-A1 NEW DIFLUOROKETAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-11-17 WO disclosed
WO-2016180751-A1 NEW DIFLUOROKETAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-11-17 WO disclosed
WO-2016135070-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-09-01 WO disclosed
US-5948807-A ANTIDOPAMINE, ANTISEROTONIN AGENTS; ALGESICS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1999-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348257-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES PRMT7, GFRA3, PRMT5 KMT2A 768/4885FFAR1 293/4885L3MBTL1 2435/4885
US-20180057526-A1 NEW DIFLUOROKETAMIDE DERIVATIVES PRMT9, CDK9, FLT3 KMT2A 283/4885FFAR1 858/4885L3MBTL1 2127/4885
US-10428108-B2 Difluoroketamide derivatives PRMT9, CDK9, FLT3 KMT2A 188/4885FFAR1 964/4885L3MBTL1 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.